Activity Preview


Treatment Options for Opioid Dependence: A Role for Agonists vs. Antagonists (Archived Webinar)

Activity Type:

  • On Demand

Release Date: 1/21/2015

Expiration Date: 1/31/2018

  • AMA PRA Category 1: 1
  • Participation: 1

Access Activity


Epidemiologic trends in opioid abuse in the U.S., including associated morbidity and mortality, will be reviewed. We will describe prescribing trends for prescription opioids in the past two decades, along with the consequences for opioid misuse. We will consider the advantages and limitations of the three primary treatment options for opioid use disorder: residential and drug-free approaches, agonist maintenance, and antagonist maintenance. The three FDA-approved medication treatments for opioid dependence will be identified. We will examine the reasons for the “treatment gap” that currently exists with respect to opioid dependence. The relative advantages of methadone vs. buprenorphine/naloxone as a choice for agonist maintenance will be considered. Strategies for detoxification and induction onto injection naltrexone will be outlined, and we will review recent findings for treatment retention with antagonist maintenance. Finally, we will consider issues of psychiatric co-morbidity or chronic pain, and how these conditions can be addressed in the context of opioid dependence treatment.

The PCSS-MAT is a collaboration of: American Academy of Addiction Psychiatry (lead), American Psychiatric Association, American Osteopathic Academy of Addiction Medicine, and the American Society of Addiction Medicine. Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Medication Assisted Treatment (5U79TI024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


  • General Member - Free
  • Resident-Fellow Member - Free
  • Non-Member - Free

Target Audience

Physicians who have a waiver to treat opioid dependence in an office-based setting and other interested clinicians.

Educational Objectives

· Participants will be able to identify three classes of treatment for opioid dependence. · Participants will be able to compare rates of relapse in opioid-dependent patients treated post-detoxification with or without medications (agonist or antagonist). · Participants will describe some of the particular benefits and challenges associated with buprenorphine/naloxone treatment for opioid dependence.

How to Earn Credit

The APA provides a CME certificate of credit for physicians and a certificate of participation for non-physicians for those who complete an evaluation. The credits claimed for completed online programs are automatically recorded in the participant transcript.

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Andrew Saxon, M.D. – Reports no financial relationships with commercial interests Beatrice Eld – Reports no financial relationships with commercial interests Disclosure of Interests: John A. Renner, Jr., M.D. – Stock/other financial options with Johnson & Johnson and General Electric Frances R. Levin, M.D. – Grant/research support: US World Meds. Maria Sullivan, M.D., Ph.D. – Associate Professor of Psychiatry at CUMC, Division of Substance Abuse, Columbia University/New York State Psychiatric Institute; stock/other financial options: Alkermes

Hardware/Software Requirements

For PC users, we recommend using a computer that is running the most recent version of Microsoft Windows.
For Macintosh users, we recommend using a computer that is running OS X or later.
Although the presentations and website can be viewed on any browser, we suggest Google Chrome for PC users and the latest version of Firefox for Macintosh users. Make sure your computer's software and browsers are updated regularly for an optimal experience.

Due to the media-rich content, we recommend viewing programs at a minimum screen resolution of 800 x 600 pixels, but preferably 1024 x 768 pixels.

Estimated Time to Complete

PROGRAM RELEASE DATE: January 20, 2015
PROGRAM END/REVIEW DATE: January 20, 2018 Contact for questions about this course Contact for technical assistance

Access Activity